The overall mission of the Virology/Immunology Core is to enhance HIV-related research and promote collaborations among HIV investigators, by providing improved access to virologic and immunologic assays, clinical specimens, and recombinant DMA constructs.
The specific aims of this Core are: 1. To provide a centralized repository for clinical specimens and HIV-related recombinant DMA constructs that can be used by clinical, behavioral, and laboratory investigators. 2. To centralize, and improve access to, state-of-the-art virologic assays for clinical, behavioral, and laboratory investigators. 3. To provide a centralized facility that produces recombinant proteins relevant to HIV research. 4. To provide expertise in the design and interpretation of flow cytometry assays, and to improve access to the shared instrumentation necessary to conduct these studies. 5. To provide improved access to existing URMC core facilities. This core will utilize and augment already existing infrastructures, such as those in the Cold Storage Facility (Aim 1), Infectious Diseases Unit laboratories (Aim 2), Human Immunology Center (Aim 4), and existing core facilities (Aim 5) at the URMC. In addition, we will centralize expression of certain recombinant proteins (Aim 3), in order to provide economy of scale to investigators that use them in HIVrelated research. The Virology/Immunology Core will implement the overall mission of the UR D-CFAR by supporting a broad base of investigators from the UR and its international collaborators in South Africa, and promoting interdisciplinary collaborations among them.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Rochester
United States
Zip Code
Leblanc, Natalie M; Mitchell, Jason (2018) Providers' Perceptions of Couples' HIV Testing and Counseling (CHTC): Perspectives From a U.S. HIV Epicenter. Couple Family Psychol 7:22-33
Rice, John D; Johnson, Brent A; Strawderman, Robert L (2018) Modeling the rate of HIV testing from repeated binary data amidst potential never-testers. Biostatistics :
Nunn, Amy; Parker, Sharon; McCoy, Katryna et al. (2018) African American Clergy Perspectives About the HIV Care Continuum: Results From a Qualitative Study in Jackson, Mississippi. Ethn Dis 28:85-92
Sillman, Brady; Bade, Aditya N; Dash, Prasanta K et al. (2018) Creation of a long-acting nanoformulated dolutegravir. Nat Commun 9:443
Ogunbajo, Adedotun; Kershaw, Trace; Kushwaha, Sameer et al. (2018) Barriers, Motivators, and Facilitators to Engagement in HIV Care Among HIV-Infected Ghanaian Men Who have Sex with Men (MSM). AIDS Behav 22:829-839
Piekna-Przybylska, Dorota; Maggirwar, Sanjay B (2018) CD4+ memory T cells infected with latent HIV-1 are susceptible to drugs targeting telomeres. Cell Cycle 17:2187-2203
Ocque, Andrew J; Hagler, Colleen E; Morse, Gene D et al. (2018) Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed Anal 156:163-169
McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62:
Piekna-Przybylska, Dorota; Nagumotu, Kavyasri; Reid, Danielle M et al. (2018) HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate. J Neurovirol :
Braksmajer, Amy; Simmons, Janie; Aidala, Angela et al. (2018) Effects of Discrimination on HIV-Related Symptoms in Heterosexual Men of Color. Am J Mens Health 12:1855-1863

Showing the most recent 10 out of 192 publications